Clinically, patients with lung cancer receiving anti-PD-1 exhibited increased magnetic resonance imaging contrast enhancement in the brain, suggestive of BBB perturbations, and increasing plasma DKK1 levels correlated with higher BrM incidence in nonresponders. Here, DKK1 is linked to lung cancer.